Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Hydrochlorothiazide ups risk of nonmelanoma skin cancer

09 Dec 2017

Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.

Researchers compared the patterns of HCTZ use between 80,162 NMSC patients and 1,603,345 age- and sex-matched controls. Those with SCC of the lip were excluded.

Conditional logistic regression analysis was used to calculate for the risk of basal cell carcinoma (BCC) or SCC with the frequency of HTCZ use. Adjustments were performed for potential confounder such as other medications and comorbidities.

The rate of high HCTZ usage in BCC patients was higher than in matched controls (2.7 vs 2.1 percent; odds ratio [OR], 1.29; 95 percent CI, 1.23 to 1.35). Similarly, significantly more SCC patients were high HCTZ users than matched controls (10.0 vs 2.8 percent; OR, 3.98; 3.68 to 4.31).

HCTZ use also showed a dose-response relationship with BCC and SCC, with those at the highest categories of exposure having the highest risks (OR for BCC, 1.54; 1.38 to 1.71; p<0.001 for trend; OR for SCC, 7.38; 6.32 to 8.60; p<0.001 for trend).

Similar trends were observed when the participants were grouped according to sex, age and tumour localization. Notably, none of the other diuretics and hypertensives showed significant relationships with the risk of SCC and BCC.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.